AR099788A1 - Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih - Google Patents
Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vihInfo
- Publication number
- AR099788A1 AR099788A1 ARP150100818A ARP150100818A AR099788A1 AR 099788 A1 AR099788 A1 AR 099788A1 AR P150100818 A ARP150100818 A AR P150100818A AR P150100818 A ARP150100818 A AR P150100818A AR 099788 A1 AR099788 A1 AR 099788A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkylene
- membered
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- -1 -ORX Chemical group 0.000 abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000001177 diphosphate Substances 0.000 abstract 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Abstract
La presente solicitud se refiere a derivados de nucleósidos sustituidos en 4 y a su uso en la inhibición de la transcriptasa inversa del VIH, en la profilaxis de una infección por el VIH, en el tratamiento de una infección por el VIH, y en la profilaxis, el tratamiento y el retraso en la aparición o en la progresión del SIDA y/o del CRS. Reivindicación 1: Un compuesto de fórmula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la que: R es un compuesto seleccionado del grupo de fórmulas (2); X es O, S, CH₂ o CF₂; Y es -CºC-R⁸ o -CºN; R¹ es -H, -C(O)R⁶, -C(O)OR⁶, -C(O)N(R⁶)₂, o un resto del grupo de fórmulas (3) o una modificación de profármaco del mono, di o trifosfato; R² es -H, -C(O)R⁶ᵃ, -C(O)OR⁶ᵃ o -C(O)N(R⁶ᵃ)₂; R³ es -H, -F u -OH; R⁴ es -H, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -haloalquilo C₁₋₆, -cicloalquilo C₃₋₇, un heteroarilo monocíclico de 5 ó 6 miembros, un heteroarilo bicíclico de 9 ó 10 miembros, halo, -CN, -NO₂, -N(RX)₂, -NH(alquileno C₁₋₆)-(heteroarilo monocíclico de 5 ó 6 miembros), -NH(alquileno C₁₋₆)-(heteroarilo bicíclico de 9 ó 10 miembros), arilo, -NHC(O)OR⁶ᵇ, -N(C(O)OR⁶ᵇ)₂, -NHC(O)N(R⁶ᵇ)₂ o -NHC(O)R⁶ᵇ, en los que cada uno de dicho grupo -alquilo C₁₋₆, dicho grupo -alquenilo C₂₋₆ o dicho grupo -alquinilo C₂₋₆ puede estar opcionalmente sustituido con halo; R⁵ es -H, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -haloalquilo C₁₋₆, -cicloalquilo C₃₋₇, un heteroarilo monocíclico de 5 ó 6 miembros, un heteroarilo bicíclico de 9 ó 10 miembros, halo, -ORX, -CN, -NO₂, -N(RX)₂, -NH(alquileno C₁₋₆)-(heteroarilo monocíclico de 5 ó 6 miembros), -NH(alquileno C₁₋₆)-(heteroarilo bicíclico de 9 ó 10 miembros), arilo, -NHC(O)OR⁶ᵇ, -N(C(O)OR⁶ᵇ)₂, -NHC(O)N(R⁶ᵇ)₂ o -NHC(O)R⁶ᵇ, en los que cada uno de dicho grupo -alquilo C₁₋₆, dicho grupo -alquenilo C₂₋₆ o dicho grupo -alquinilo C₂₋₆ puede estar opcionalmente sustituido con halo; R⁶, R⁶ᵃ y R⁶ᵇ se eligen cada uno independientemente en cada aparición de entre -H, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(arilo), -(alquileno C₁₋₃)ₘ-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C₁₋₃)ₘ-(heteroarilo monocíclico de 5 ó 6 miembros) o -(alquileno C₁₋₃)ₘ-(heteroarilo bicíclico de 9 ó 10 miembros), en los que cada uno de dicho -alquilo C₁₋₆, dicho grupo cicloalquilo C₃₋₇, dicho grupo arilo, dicho grupo heterocicloalquilo de 4 a 7 miembros, dicho grupo -(heteroarilo monocíclico de 5 ó 6 miembros) o dicho grupo (heteroarilo bicíclico de 9 ó 10 miembros) puede estar opcionalmente sustituido con R⁷; m es un número entero elegido entre 0 (cero) ó 1; R⁷ representa entre uno y cinco grupos sustituyentes, elegidos cada uno independientemente de entre -alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, arilo o un heteroarilo de 5 ó 6 miembros; R⁸ es -H, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -cicloalquilo C₃₋₇, arilo, un heteroarilo monocíclico de 5 ó 6 miembros o un heteroarilo bicíclico de 9 a 10 miembros; R⁹ es -H, halo, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -CN, -ORY o -N(RY)₂; RX se elige independientemente en cada aparición de entre -H, -alquilo C₁₋₆, -haloalquilo C₁₋₆, arilo o un heteroarilo monocíclico de 5 ó 6 miembros; o cuando alguno o ambos de R⁴ o R⁵ es -N(RX)₂, cada RX puede estar opcionalmente unido junto con el nitrógeno al que están ambos unidos para formar un heteroarilo monocíclico de 5 ó 6 miembros o un heteroarilo bicíclico de 9 ó 10 miembros; y RY es -H, -alquilo C₁₋₆ o -haloalquilo C₁₋₆; con la condición de que cuando X es O, Y es -CºCH o -CºN, R¹ es -H, R² es -H, R⁴ es -NH₂, R⁵ es -H, -F, u -OH y R⁹ es -F entonces R³ no es -F.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074294 WO2015143712A1 (en) | 2014-03-28 | 2014-03-28 | 4'-substituted nucleoside reverse transcriptase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099788A1 true AR099788A1 (es) | 2016-08-17 |
Family
ID=52824598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100818A AR099788A1 (es) | 2014-03-28 | 2015-03-18 | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih |
Country Status (41)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41213A (fr) * | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| CN108289931B (zh) * | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
| JP7125714B2 (ja) * | 2016-12-13 | 2022-08-25 | ヤマサ醤油株式会社 | 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体 |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| CR20200126A (es) * | 2017-09-18 | 2020-07-11 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS |
| CA3087192A1 (en) * | 2017-12-27 | 2019-07-04 | Raymond F. Schinazi | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents |
| JP2021515771A (ja) * | 2018-03-07 | 2021-06-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ療法に有用な化合物 |
| CA3095646A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| CN112996511A (zh) * | 2018-07-09 | 2021-06-18 | 默沙东公司 | 4’-乙炔基核苷类似物的酶促合成 |
| AR115936A1 (es) * | 2018-08-09 | 2021-03-17 | Glaxosmithkline Ip No 2 Ltd | Compuestos útiles en terapia del vih |
| SG11202107145SA (en) | 2019-01-25 | 2021-08-30 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| CA3132112A1 (en) * | 2019-03-06 | 2020-09-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| CN110054654B (zh) * | 2019-05-27 | 2022-12-27 | 武汉百科药物开发有限公司 | 一种地西他滨中间体α-取代脱氧核糖的合成方法 |
| AU2020346908A1 (en) * | 2019-09-11 | 2022-03-24 | The Scripps Research Institute | Antiviral prodrugs and formulations thereof |
| CA3164528A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN112321589B (zh) * | 2020-02-18 | 2022-05-03 | 山东科巢生物制药有限公司 | 一种抗病毒药物瑞德西韦及其中间体的合成方法 |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| CN113527303B (zh) * | 2020-04-21 | 2022-06-10 | 浙江工业大学 | 一种瑞德西韦母核中间体的制备工艺 |
| CN113637041B (zh) * | 2020-05-11 | 2024-02-27 | 上海科胜药物研发有限公司 | 一种核糖核苷的制备方法 |
| US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| CN112300236A (zh) * | 2020-10-21 | 2021-02-02 | 佛山科学技术学院 | 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用 |
| TW202237146A (zh) | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
| US11793827B2 (en) | 2021-01-25 | 2023-10-24 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| KR20240050362A (ko) | 2021-08-20 | 2024-04-18 | 시오노기 앤드 컴파니, 리미티드 | 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그 |
| WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| DE69133405T2 (de) | 1990-01-11 | 2005-07-07 | Isis Pharmaceutical, Inc., Carlsbad | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
| CZ126799A3 (cs) | 1996-10-16 | 1999-07-14 | Icn Pharmaceuticals | Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují |
| EP1177201B1 (en) | 1999-05-12 | 2003-09-24 | Yamasa Corporation | 4'-c-ethynyl pyrimidine nucleosides |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| WO2005003047A1 (en) | 2003-07-03 | 2005-01-13 | Philips Intellectual Property & Standards Gmbh | Pane which can be heated by means of invisible light |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| AU2007215114A1 (en) | 2006-02-14 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CN101003550B (zh) * | 2006-12-30 | 2010-05-19 | 河南省分析测试研究中心 | 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途 |
| MX2009007333A (es) | 2007-01-12 | 2009-08-31 | Biocryst Pharm Inc | Analogos de nucleosidos antivirales. |
| CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| WO2009132135A1 (en) | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | 1' -substituted carba-nucleoside analogs for antiviral treatment |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| CN102216316A (zh) | 2008-09-05 | 2011-10-12 | 寿制药株式会社 | 取代胺衍生物及以其为有效成分的药物组合物 |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| DE102009000180A1 (de) | 2009-01-13 | 2010-07-15 | Evonik Degussa Gmbh | Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| AU2010226466A1 (en) | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| CN102858767B (zh) | 2009-12-17 | 2015-08-19 | 默沙东公司 | 作为syk抑制剂的氨基嘧啶 |
| KR20130083389A (ko) | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 |
| CR20170278A (es) | 2010-07-22 | 2017-09-29 | Gilead Sciences Inc | Métodos y compuestos para tratar infecciones virales por paramyxoviridae |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| EP3351552B1 (en) | 2012-03-13 | 2021-05-19 | Gilead Sciences, Inc. | 2'-substituted carba-nucleoside analogs for antiviral treatment |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
-
2014
- 2014-03-28 WO PCT/CN2014/074294 patent/WO2015143712A1/en active Application Filing
-
2015
- 2015-03-18 AR ARP150100818A patent/AR099788A1/es active IP Right Grant
- 2015-03-19 JO JOP/2015/0049A patent/JO3636B1/ar active
- 2015-03-20 TW TW104109078A patent/TWI660967B/zh active
- 2015-03-26 SG SG11201608031PA patent/SG11201608031PA/en unknown
- 2015-03-26 RS RS20211236A patent/RS62418B1/sr unknown
- 2015-03-26 AU AU2015236018A patent/AU2015236018B2/en active Active
- 2015-03-26 CN CN201580029472.2A patent/CN106795199B/zh active Active
- 2015-03-26 PT PT157159344T patent/PT3122752T/pt unknown
- 2015-03-26 EP EP15715934.4A patent/EP3122752B1/en active Active
- 2015-03-26 KR KR1020167029801A patent/KR101961009B1/ko active IP Right Grant
- 2015-03-26 SI SI201531716T patent/SI3122752T1/sl unknown
- 2015-03-26 LT LTEPPCT/US2015/022621T patent/LT3122752T/lt unknown
- 2015-03-26 CA CA2943792A patent/CA2943792C/en active Active
- 2015-03-26 DK DK15715934.4T patent/DK3122752T3/da active
- 2015-03-26 PE PE2016001816A patent/PE20170197A1/es unknown
- 2015-03-26 US US14/669,398 patent/US9777035B2/en active Active
- 2015-03-26 HR HRP20211622TT patent/HRP20211622T1/hr unknown
- 2015-03-26 WO PCT/US2015/022621 patent/WO2015148746A1/en active Application Filing
- 2015-03-26 PL PL15715934T patent/PL3122752T3/pl unknown
- 2015-03-26 HU HUE15715934A patent/HUE056913T2/hu unknown
- 2015-03-26 MD MDA20160117A patent/MD4812C1/ro active IP Right Grant
- 2015-03-26 JP JP2016559266A patent/JP6182680B2/ja active Active
- 2015-03-26 MY MYPI2016001741A patent/MY194635A/en unknown
- 2015-03-26 NZ NZ724343A patent/NZ724343A/en unknown
- 2015-03-26 ES ES15715934T patent/ES2894228T3/es active Active
- 2015-03-26 GE GEAP201514307A patent/GEP20197009B/en unknown
- 2015-03-26 AP AP2016009482A patent/AP2016009482A0/en unknown
- 2015-03-26 MX MX2016012659A patent/MX367058B/es active IP Right Grant
- 2015-03-26 CR CR20160451A patent/CR20160451A/es unknown
- 2015-03-26 EA EA201691931A patent/EA031476B1/ru not_active IP Right Cessation
- 2015-03-26 UA UAA201610777A patent/UA120758C2/uk unknown
- 2015-03-26 MA MA39809A patent/MA39809B1/fr unknown
-
2016
- 2016-09-19 IL IL247923A patent/IL247923B/en active IP Right Grant
- 2016-09-26 NI NI201600145A patent/NI201600145A/es unknown
- 2016-09-26 PH PH12016501897A patent/PH12016501897A1/en unknown
- 2016-09-26 CL CL2016002414A patent/CL2016002414A1/es unknown
- 2016-09-28 GT GT201600201A patent/GT201600201A/es unknown
- 2016-09-28 SV SV2016005290A patent/SV2016005290A/es unknown
- 2016-09-28 DO DO2016000265A patent/DOP2016000265A/es unknown
- 2016-10-28 EC ECIEPI201685206A patent/ECSP16085206A/es unknown
-
2017
- 2017-08-24 US US15/685,824 patent/US20180002366A1/en not_active Abandoned
- 2017-09-07 AU AU2017225090A patent/AU2017225090B2/en active Active
-
2021
- 2021-10-25 CY CY20211100925T patent/CY1124829T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR090847A1 (es) | Compuestos moduladores del receptor huerfano retinoideo (ror) | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR091939A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
| AR097756A1 (es) | Derivados de fenilalanina sustituidos | |
| AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR100733A1 (es) | Derivados de difluoroetilpiridina como antagonistas del receptor nmda nr2b | |
| AR108610A1 (es) | Derivados de imidazolona inhibidores de la elastasa de neutrófilos humana | |
| AR104293A1 (es) | Indazolonas como moduladores de la señalización de tnf | |
| AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |